First report of vancomycin-resistant Enterococcus faecium isolated in Poland W. Hryniewicz, K. Szczypa, M. Bronk, A. Samet, A. Hellmann, K. Trzcinski Clinical Microbiology and Infection Volume 5, Issue 8, Pages 503-505 (August 1999) DOI: 10.1111/j.1469-0691.1999.tb00181.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 1 RAPD products obtained in PCR reactions using ERIC1, AP4 and ERIC1/AP4 primers. Molecular size markers are indicated (S1, λ/BstEII; S2, pBR 322/MspI). Lane 1, isolate 1 (1639); lane 2, isolate 2 (1640); lane 3, isolate 3 (1641). Clinical Microbiology and Infection 1999 5, 503-505DOI: (10.1111/j.1469-0691.1999.tb00181.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 2 Pulsed-field gel electrophoresis of BilII-digested chromosomal DNA from E. faecium isolates. Molecular masses (in kilobases) were obtained from bacteriophage DNA concatamers (S). Lane 1, isolate 1 (1639); lane 2, isolate 2 (1640); lane 3, isolate 3 (1641). Clinical Microbiology and Infection 1999 5, 503-505DOI: (10.1111/j.1469-0691.1999.tb00181.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 3 Products of specific PCR amplification of vanA gene. Molecular size markers are indicated. (S1, λ/βstΕII; S2, pBR 322/MspI). Lane 1, glycopeptide-susceptible E. faecium BM4147–1; lane 2, glycopeptide-resistant E. faecium BM4147; lane 3, isolate 1 (1639); lane 4, isolate 2 (1640); lane 5, isolate 3 (1641). Clinical Microbiology and Infection 1999 5, 503-505DOI: (10.1111/j.1469-0691.1999.tb00181.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions